

The generation of knock-in mice expressing fluorescently tagged galanin receptors 1 and 2



Niall Kerr^{a,1}, Fiona E. Holmes^a, Sally-Ann Hobson^a, Penny Vanderplank^a, Alan Leard^b,
Nina Balthasar^a, David Wynick^{a,*}

^a Schools of Physiology and Pharmacology and Clinical Sciences, Medical Sciences Building, University Walk, Bristol BS8 1TD, UK

^b Wolfson Bioimaging Facility, Medical Sciences Building, University Walk, Bristol BS8 1TD, UK

ARTICLE INFO

Article history:

Received 20 May 2015

Revised 6 August 2015

Accepted 10 August 2015

Available online 17 August 2015

Keywords:

GalR1

GalR2

Dorsal root ganglion

Spinal cord

Brain

uORF

ABSTRACT

The neuropeptide galanin has diverse roles in the central and peripheral nervous systems, by activating the G protein-coupled receptors Gal₁, Gal₂ and the less studied Gal₃ (*GalR1–3* gene products). There is a wealth of data on expression of Gal_{1–3} at the mRNA level, but not at the protein level due to the lack of specificity of currently available antibodies. Here we report the generation of knock-in mice expressing Gal₁ or Gal₂ receptor fluorescently tagged at the C-terminus with, respectively, mCherry or hrGFP (humanized *Renilla* green fluorescent protein). In dorsal root ganglia (DRG) neurons expressing the highest levels of Gal₁-mCherry, localization to the somatic cell membrane was detected by live-cell fluorescence and immunohistochemistry, and that fluorescence decreased upon addition of galanin. In spinal cord, abundant Gal₁-mCherry immunoreactive processes were detected in the superficial layers of the dorsal horn, and highly expressing intrinsic neurons of the lamina III/IV border showed both somatic cell membrane localization and outward transport of receptor from the cell body, detected as puncta within cell processes. In brain, high levels of Gal₁-mCherry immunofluorescence were detected within thalamus, hypothalamus and amygdala, with a high density of nerve endings in the external zone of the median eminence, and regions with lesser immunoreactivity included the dorsal raphe nucleus. Gal₂-hrGFP mRNA was detected in DRG, but live-cell fluorescence was at the limits of detection, drawing attention to both the much lower mRNA expression than to Gal₁ in mice and the previously unrecognized potential for translational control by upstream open reading frames (uORFs).

© 2015 university of bristol. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Galanin is a 29–30 amino acid neuropeptide that is dramatically induced after peripheral or central nervous system injury, and plays physiological roles in nociception, memory and cognition, anxiety-related behaviours, feeding, reproduction, neurite outgrowth and as a

Abbreviations: AOTF, acousto-optic tunable filter; BAC, bacterial artificial chromosome; CDS, coding sequence; CMV, cytomegalovirus; DOR, δ -opioid receptor; DR, dorsal raphe nucleus; DRG, dorsal root ganglia; EGFP, enhanced green fluorescent protein; ER, endoplasmic reticulum; ES cell, embryonic stem cell; FRT sites, FLP recombination target sites; GALP, galanin-like peptide; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; GFP, green fluorescent protein; GPCRs, G protein-coupled receptors; hrGFP, humanized *Renilla* green fluorescent protein; ISH, in situ hybridization; LSN, lateral spinal nucleus; ME, median eminence; NPY, neuropeptide Y; nt, nucleotides; RNA-seq, next generation RNA sequencing; RT-PCR, reverse transcription polymerase chain reaction; TSA, tyramide signal amplification; UTR, untranslated region; uORFs, upstream open reading frames.

* Corresponding author.

E-mail address: d.wynick@bristol.ac.uk (D. Wynick).

¹ Current address: MRC Harwell, Didcot, Oxfordshire OX11 0RD, UK.

neuronal trophic factor (Cortes et al., 1990; Lang et al., 2015; Villar et al., 1989; Webling et al., 2012). The N-terminal 15 residues of galanin are strictly conserved between species and the N-terminal end is essential for biological activity (Lang et al., 2015; Webling et al., 2012), binding to the three galanin receptor subtypes Gal₁, Gal₂ and Gal₃ (*GalR1–3* gene products), which are each Class A rhodopsin-like G protein-coupled receptors (GPCRs) that differ in sites of expression, functional coupling and signalling activities (Webling et al., 2012). The phenotypes of mice deficient in each of the galanin receptors have recently been reviewed (Brunner et al., 2014; Lang et al., 2015; Webling et al., 2012). Gal_{1–3} are also bound by galanin-like peptide (GALP), but not by the GALP alternatively spliced product alarin (Webling et al., 2012), and recently the neuropeptide spexin/NPQ (neuropeptide Q) was also reported to bind to Gal₂ and Gal₃, but not to Gal₁ (Kim et al., 2014).

In adult rat the expression of Gal₁ mRNA is largely restricted to brain, spinal cord and dorsal root ganglia (DRG), whereas Gal₂ mRNA is also detected in several peripheral tissues such as large intestine and uterus. In contrast, Gal₃ mRNA has a more restricted distribution within brain,

is rare in spinal cord and rare or not present in DRG, and expression in peripheral tissues is controversial (Burazin et al., 2000; Howard et al., 1997; O'Donnell et al., 1999; Shi et al., 2006; Waters and Krause, 2000; Webling et al., 2012). By in situ hybridization (ISH), Gal₁ mRNA is more highly expressed than Gal₂ overall in brain (Burazin et al., 2000) and by far the highest levels of Gal₂ detected in the nervous system are in the DRG (O'Donnell et al., 1999).

In adult mouse brain the distribution of Gal₁ mRNA by ISH is largely similar to rat (Hohmann et al., 2003), whereas the absence of specific [¹²⁵I]-galanin binding sites in any region of adult Gal₁-deficient brain (Jungnickel and Gundlach, 2005) suggests a species-specific, greatly reduced expression of Gal₂ mRNA. However, it is still detectable by the more sensitive RT-PCR method in both mouse whole brain (Hobson et al., 2006; Jacoby et al., 2002) and subregions including the amygdala, hippocampus and hypothalamus (Brunner et al., 2014; Hawes et al., 2005; He et al., 2005; Shi et al., 2006; Zhao et al., 2013), as well as in spinal cord (Jacoby et al., 2002), DRG, trigeminal and nodose sensory ganglia (Hobson et al., 2006; Page et al., 2007) and several peripheral tissues (Barreto et al., 2011; Hobson et al., 2006; Jacoby et al., 2002; Kim and Park, 2010; Pang et al., 1998). Less work has been reported on Gal₃ mRNA expression, but by RT-PCR it is detected in mouse whole brain and some subregions (Brunner et al., 2014; Hawes et al., 2005; Zhao et al., 2013), nodose ganglion (Page et al., 2007) and several peripheral tissues (Barreto et al., 2011; Brunner et al., 2014; Kim and Park, 2010), but is at the limits of detection in both spinal cord and DRG (Hobson et al., 2006; Jacoby et al., 2002).

Current antibodies against Gal₁ or Gal₂ are non-selective under standard immunodetection conditions, with identical immunoreactivity patterns in wild-type and receptor knockout mice (Hawes and Picciotto, 2005; Lang et al., 2015; Lu and Bartfai, 2009; F.E.H., P.V. and D.W., unpublished). To delineate the expression of Gal₁ and Gal₂ at the protein level we wished to tag each receptor with fluorochromes. The C-terminal tagging of GPCRs with green fluorescent protein (GFP) is generally thought to have no significant effect on GPCR properties e.g. ligand binding, signal transduction and intracellular trafficking (Ceredig and Massotte, 2014), and both Gal₁ and Gal₂ have been shown to be functional when C-terminally tagged with enhanced GFP (EGFP) or its variants and expressed in cell lines (Wirz et al., 2005; Xia et al., 2004, 2008). The GPCR superfamily is the largest group of cell surface receptors and are the targets of around one third of marketed drugs, yet to date the only knock-in mice that express a fluorescently-tagged GPCR are Rhodopsin-EGFP and two rhodopsin mutant variants, δ-opioid receptor (DOR)-EGFP and the recently reported μ-opioid receptor (MOR)-mCherry (Ceredig and Massotte, 2014; Erbs et al., 2015; Scherrer et al., 2006). Transgenic mice have been successfully generated expressing either humanized *Renilla* GFP (hrGFP; Stratagene-Agilent; Zeng et al., 2003) under the control of various endogenous promoters (Sakata et al., 2009; van den Pol et al., 2009; Voigt et al., 2012), or with widespread expression of the monomeric red fluorescent protein mCherry under the control of a ubiquitin-C promoter (Fink et al., 2010; Shaner et al., 2004). Here we describe the generation and initial characterization of Gal₁-mCherry and Gal₂-hrGFP knock-in mice, focussing on expression in DRG, spinal cord and brain.

2. Materials and methods

2.1. DNA sequence analysis

Planning for knock-in gene characterizations used mouse reference genome Build 37.1, vector hrGFP-FRTneoFRT (see below, Section 2.2) and mCherry cDNA (AY678264) sequences. The RepeatMasker 3.2.9 programme (Smit, Hubley and Green, 1996–2010, <http://www.repeatmasker.org>) was used to select regions of the *GalR1* or *GalR2* genes for retrieval target sites or Southern probes that avoided repetitive DNA elements, and homology arm targets that minimized the

presence of repetitive DNA elements. Ribosome profiling data (Ingolia et al., 2011) was accessed using the GWIPS-viz. browser (<http://gwips.ucc.ie>; Michel et al., 2014). The ribosome density peaks for the uORF6 and *GalR2* initiation codons were at, respectively, Chr11 nucleotides (nt) 116,281,254–286 and 116,281,474–509 of the GRCm38/mm10 genome assembly (GWIPS-viz. ribo-seq coverage plot; Ingolia et al., 2011; Michel et al., 2014).

2.2. Generation of *GalR1*-mCherry-[*neo*⁺] and *GalR2*-hrGFP-[*neo*⁺] knock-in mice

Mouse genomic clones including either *GalR1* or *GalR2* genes from the bMQ mouse strain 129S7 (129Sv) bacterial artificial chromosome (BAC) library (inserts 89–178 kb; Source BioScience; Adams et al., 2005) were electroporated into strain EL250 *Escherichia coli* (Lee et al., 2001). This allowed temperature-inducible, lambda Red-mediated, homologous recombination into the BAC (Copeland et al., 2001; Lee et al., 2001) of PCR products from either vector hrGFP-FRTneoFRT (Balthasar et al., 2004; Parton et al., 2007; hrGFP derived from Stratagene-Agilent vector phrGFP-1, Zeng et al., 2003; Fig. 2A, middle panel) flanked by *GalR2* homologous sequence or vector mCherry-FRTneoFRT (hrGFP exchanged for mCherry; Shaner et al., 2004) flanked by *GalR1* homologous sequence. Within the latter PCR product an *Asel* restriction site was introduced immediately downstream of the 3' FRT site (Fig. 1A, middle panel), for use in Southern blot digests, and the mCherry/hrGFP heterologous 3'-untranslated region (UTR) has identity to nt 705–1193 of vector pCMV-Script (AF028239) which includes the SV40 early region poly(A) site (Connelly and Manley, 1988; J02400, nt 2828–2547). Correct insertion into the BAC was validated by DNA sequencing of cloned PCR products of each junction. All DNA sequencing was by Source BioScience, Oxford.

Retrieval from the recombinant BAC clones by gap repair (Copeland et al., 2001; Lee et al., 2001) into PCR-amplified vector pCR-Blunt (Invitrogen) was mediated by either *GalR1* target sequences with adjacent introduced rare *SwaI* restriction sites, or *GalR2* target sequences with adjacent introduced *BstZ171* restriction sites. Recombined plasmid DNAs were transformed into STBL3 *E. coli* (Invitrogen) and the final targeting constructs were excised with either *SwaI* (*GalR1*-mCherry-FRTneoFRT; 11.3 kb, with *GalR1* homology arms of 4.2 and 3.9 kb) or *BstZ171* (*GalR2*-hrGFP-FRTneoFRT; 8.1 kb, with *GalR2* homology arms of 2.3 and 2.7 kb).

Targeting construct inserts were electroporated into embryonic stem (ES) cell line E14.1a (strain 129P2/OlaHsd; Downing and Battey, 2004; Hooper et al., 1987) and the SV40-*neo* cassette selected with 250 μg/ml G418 by Geneta (Dept. of Biochemistry, University of Leicester). G418-resistant ES cell clones were screened for correct targeting by PCR (data not shown) and real-time quantitative genomic PCR, and expanded clones were screened by Southern blot analysis (Supplementary Materials and Methods). Selected clones were karyotyped to confirm euploidy, and three ES cell clones of each knock-in gene were injected into 3.5 day old blastocysts from C57BL/6J mice to produce chimeric mice (Geneta). These were crossed to strain 129P2/OlaHsd mice and germline transmission was assessed by PCR genotyping (see below).

2.3. Animals

Mice were housed in a temperature- and humidity-controlled colony on a 14:10 h light-dark cycle, and fed standard chow and water ad libitum. Procedures were carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines. Ear-punch biopsies were used for PCR genotyping, animals were killed by cervical dislocation to obtain DRG for RT-PCR analysis (Section 2.6), or primary DRG cultures (Section 2.7). Three mice had peripheral transection of the right sciatic nerve prior to perfusion seven days later to obtain ipsilateral (axotomized) lumbar L4 and L5 DRG (Holmes et al., 2008) for immunohistochemistry (Section 2.9).




Fig. 1. Gene-targeting of *GalR1* and genotype analysis. (A) Schematic diagram of endogenous *GalR1* (top panel), knock-in *GalR1*-mCherry-[*neo*⁺] (middle panel) and knock-in *GalR1*-mCherry-[Δ *neo*] (bottom panel) alleles. Indicated relative locations are *GalR1* exon 3 with coding sequence (CDS; black filled box) and endogenous 3'-UTR ('UTR'; NM_008082, not full-length), and restriction sites AseI (A), BsrGI (Bs) and BamHI (B). The knock-in *GalR1*-mCherry-[*neo*⁺] DNA (middle panel) includes the following elements: the targeting construct (grey horizontal thickened line); the 3' end of the *GalR1* CDS joined in-frame by a 21 nucleotide linker, encoding the flexible linker RDPVAV (Gibbs et al., 2003; Lobbstaal et al., 2010), to mCherry CDS (diagonal banded box; mCherry protein sequence AAV52164); a heterologous 3'-UTR including the SV40 early region poly(A) site (grey filled box); downstream FRT sites (right arrowheads) flanking a SV40-*neo* cassette selection marker with a HSV (herpes simplex virus) thymidine kinase (*TK*) poly(A) site; an introduced AseI restriction site (A) immediately downstream of the 3' FRT site; and the endogenous 3'-UTR ('UTR') (see Materials and methods section). Locations of external 5' and 3' probes, *neo* probe, and hybridizing DNA fragments are also shown (see Supplementary Fig. 1A for more detailed image of [*neo*⁺] allele). Note that in the *GalR1*-mCherry-[Δ *neo*] knock-in allele (bottom panel) the SV40-*neo* cassette flanked by FRT sites has been removed by FLPe. (B) Southern blot analysis validates correct insertion of the targeting construct. Wild-type (W) and *GalR1*-mCherry-[Δ *neo*] knock-in line 33 (K) mouse tail DNA were digested and hybridized with: BsrGI and *GalR1* 5' external probe (left panel; W: 7821 bp, K: 6158 bp); AseI and *GalR1* 3' external probe (middle panel; W: 12,924 bp, K: 5386 bp); and BamHI and *neo* probe, which only hybridized to positive-control heterozygous *GalR1*-mCherry-[*neo*⁺] ES cell clone 33 (right panel; lane N: 3030 bp). The relative distance travelled by DNA ladder fragments (1 kb Plus, Life Technologies) is indicated in kb on the left of each panel.

2.4. PCR genotyping to distinguish knock-in from endogenous receptor alleles

Mouse PCR genotyping for *GalR1* used the three primers 5'-AGCCTTCCCAGTACGCCAGCTT-3', 5'-CAGAACTACTTTACACCATGGAGATC-3' and 5'-TCGAACTCGTGGCCGTTACACCGA-3', which amplified an endogenous *GalR1* product of 547 bp and a *GalR1*-mCherry knock-in product of 348 bp. PCR genotyping for *GalR2* used primers 5'-CGAGGAGAGCTTCA GGCCGAGT-3', 5'-CACCTGTAAAGTCCCAGAGACGT-3' and 5'-CTGGTTCCGCAACAGGATGTTGC-3', which amplified an endogenous *GalR2* product of 543 bp and a *GalR2*-hrGFP knock-in product of 308 bp. PCRs with FastStart Taq DNA polymerase (Roche) and HPLC-purified primers (MWG Eurofins) used cycling conditions of 94 °C for 7 min, 40 cycles of [94 °C, 30 s; 63 °C, 45 s; 72 °C, 45 s], and a final 72 °C incubation for 10 min.

2.5. Deletion of the FRT-flanked SV40-*neo* cassette from knock-in mice

Homozygous strain C57BL/6J *ACTB:FLPe* transgenic mice (Buchholz et al., 1998; Rodriguez et al., 2000) from the Bristol University colony (provided by Dr. Alastair Poole and N.B.) were PCR genotyped using primers 5'-CAATACCTGATCACTACTTCGCACT-3' and 5'-CATGTCTGATCCTCGAGGAGCTC-3' under standard cycling conditions (Section 2.4), which amplified the expected 362 bp sequenced product.

Heterozygous *GalR1*-mCherry-[*neo*⁺] knock-in mice were crossed to *ACTB:FLPe* transgenic mice, and offspring both heterozygous for *GalR1*-mCherry and genetically mosaic for deletion of the SV40-*neo* cassette (Δ *neo*) by PCR genotyping (i.e. both Δ *neo* and *neo*⁺) were then crossed to strain 129P2/OlaHsd. Offspring were PCR genotyped in separate reactions for *GalR1*-mCherry heterozygosity (Section 2.4), presence of *neo* and presence of Δ *neo*. Primers for presence of *neo* were 5'-GCATACGCTT GATCCGGTACCT-3' and 5'-CTCCTTCCGTGTTTCAGTACCT-3 (630 bp product), and for presence of Δ *neo* were 5'-GTCTGTTTCATGATCATAATC AGCCAT-3' (UTR-F; heterologous 3'-UTR sequence) and 5'-CAGAACTT

ACTTTACACCATGGAGATC-3' (*GalR1R*) which amplified the expected 626 bp sequenced product. A similar breeding strategy was used with the heterozygous *GalR2*-hrGFP-[*neo*⁺] knock-in mice, except that primers for presence of Δ *neo* were UTR-F and 5'-CCTCAAACCTTGATGGCTTGCTT TG-3' (*GalR2R*) which with annealing at 65 °C amplified the expected 528 bp sequenced product.

Frozen sperm from homozygous *GalR1*-mCherry (line 33) or *GalR2*-hrGFP (line 32) knock-in mice were deposited at the MRC Frozen Embryo and Sperm Archive and are available from <https://www.infrafrontier.eu/> (*GalR1*-mCherry, EMMA stock ID EM:08192; *GalR2*-hrGFP, EMMA stock ID EM:08193).

2.6. Real-time quantitative RT-PCR

Lumbar DRG from individual, age-matched 7–8 week old wild-type, *GalR1*-mCherry or *GalR2*-hrGFP mice (each *n* = 5; 1 male, 4 females) were frozen on dry ice and stored at –80 °C, prior to total RNA isolation and reactions containing reverse transcriptase (RT+) or without enzyme (RT– control) (Kerr et al., 2004). Real-time quantitative RT-PCR (reverse transcription polymerase chain reaction) assays and primer and probe sets (Applied Biosystems) for *Gal1*, *Gal2*, galanin and endogenous control glyceraldehyde 3-phosphate dehydrogenase (*Gapdh*) were as reported (Hobson et al., 2006), except for the corrected *Gal2* probe sequence 5'-TTCTCACTATGACGCCAGCAGC-3' (m*GalR2*-46TAQ) used then and herein. Relative mRNA expression levels were derived by the comparative threshold cycle (*C_t*) method ($2^{-\Delta\Delta C_t}$) normalized to *Gapdh* (Hobson et al., 2006), with results presented as mean of log transformed data plus SEM. Sample identities were confirmed by standard RT-PCR for *Gal1*-mCherry and *Gal2*-hrGFP receptor-fluorescent tag products (data not shown).

2.7. DRG culture and live-cell imaging

DRG cultures from 8 week old mice (Hobson et al., 2013) were generated from individual animals, and neurons were replated onto

glass-bottom microwell dishes (MatTek) treated with 0.5 mg/ml polyornithine and 5 µg/ml laminin (Sigma). Immediately prior to imaging, medium was changed to air-buffered L15 (Sigma) supplemented with 5% horse serum, 1 mM L-glutamine and 10 ng/ml gentamicin. Cell images were recorded using a Leica TCS SP8 confocal system with enhanced sensitivity due to the GaAsP Hybrid detector (HyD), attached to a Leica DMI6000 inverted epifluorescence microscope with a 63×/1.30 Glycerol objective lens (Leica Microsystems), at 37 °C. Imaging parameters were selected to optimize confocal resolution. Specifically, GalR1-mCherry was detected by excitation with a HeNe 594 nm laser (Anderson et al., 2006; 80% acousto-optic tunable filter, AOTF) and emission detected at 600–660 nm with 330% gain, 6× line accumulation, and 2× frame averaging. GalR2-hrGFP was detected by excitation with a 488 nm argon laser (35% power, with 70% AOTF) and emission detected at 492–538 nm with 400% gain, 6× line accumulation, and 2× frame averaging. Confocal images were detected as z stacks of x–y images taken at 1 µm intervals, and were acquired using LCS (Leica) software. Images designated 'adjusted' used linear brightness/contrast functions of Adobe Photoshop software.

2.8. Receptor internalization studies and quantification of somatic cell membrane associated fluorescence

Immediately prior to imaging the medium was changed to FluoroBrite DMEM (Life Technologies) to decrease background fluorescence, with medium supplements B-27 (Life Technologies), 1 mM L-glutamine and 10 ng/ml gentamicin. Imaging was at 37 °C with 5% CO₂ enrichment. Single focal planes were imaged to reduce potential photo-bleaching, with 6× line accumulation and without frame averaging. Porcine galanin (1–29) was from Bachem. Quantification of somatic cell membrane fluorescence (Scherrer et al., 2006) of GalR1-mCherry from original confocal images used Volocity software (Perkin Elmer) to define both the area within the cell membrane (intracellular fluorescence) and between this and the outside of the somatic cell membrane (surface fluorescence). Results are presented as mean plus SEM.

2.9. Immunohistochemical staining

Mice were deeply anaesthetised and transcardially perfused with PBS followed by 4% paraformaldehyde/PBS. Brains, lumbar spinal cords and lumbar L4 and L5 DRGs were dissected and post-fixed for 24 h in 4% paraformaldehyde/PBS then transferred to 20% sucrose/PBS for 24 h at 4 °C. Spinal cords and DRG were placed in OCT embedding matrix (CellPath) and frozen on dry ice, and brains were frozen on dry ice. Tissue was stored at –80 °C until use. 10 µm sections of DRG and 30 µm sections of spinal cord and brain were cut on a cryostat. DRG were collected directly onto Polysine slides (Thermo Scientific), or after immunohistochemical processing of floating sections for brain and cord. mCherry was detected using the TSA™ (tyramide signal amplification) Plus Fluorescein System (PerkinElmer). Sections were processed at room temperature as follows: incubated in 0.3% H₂O₂/PBS for 30 min to quench endogenous peroxidase; washed 1 × 5 min with TN (0.1 M Tris–HCl, pH 7.5; 0.15 M NaCl); blocked for 30 min in TNB (0.5% Blocking Reagent in TN); and incubated for 18 h in rabbit anti-DsRed antibody (*Discosoma* red fluorescent protein; Erbs et al., 2015; Voigt et al., 2012; Clontech cat. no. 632,496) diluted 1:500 in TNB. Sections were washed 3 × 5 min in TN; incubated in HRP anti-rabbit IgG (Vector Laboratories cat. no. PI-1000) diluted 1:200 in TNB for 1 h; washed 3 × 5 min in TN; incubated in fluorescein-conjugated tyramide (TSA™ Plus Fluorescein System; PerkinElmer) at 1:50 for 10 min. Sections were washed 3 × 10 min in TN, floating sections collected onto slides, then all sections mounted in Vectashield (Vector Laboratories) and coverslipped. Immunohistochemistry of wild-type tissue verified the specificity of the primary antibody, and omission of the primary antibody verified the absence of non-specific staining by the secondary antibody.

The polyclonal anti-hrGFP antibody (Sakata et al., 2009; Zhang et al., 2013; Stratagene-Agilent 240,142) was used as above diluted at 1:500 or 1:5000 on DRG (± axotomy) and brain, and at 1:500–1:30,000 on spinal cord (± axotomy), each with wild-type control tissue.

Gal₁-mCherry immunofluorescence was detected by excitation with a 488 nm argon laser and emission detected at 492–538 nm on a Leica TCS SP5-II confocal system attached to a Leica DMI6000 inverted epifluorescence microscope with dry 20× or oil 40× objective lens. Confocal images were detected as z stacks of x–y images taken at 1 µm (DRG/brain) or 2 µm (cord, unless stated in Fig. 6N and O) intervals with 4× line accumulation, and selected images extracted using Volocity software (Perkin Elmer). Photomicrographs of Gal₁-mCherry immunofluorescence in brain at lower magnifications (2.5×, 5×) used IM50 Image Manager software (Leica; Holmes et al., 2008) with gain set at 1 (Fig. 7), as constrained by high immunoreactivity in thalamic nuclei, and regions with lesser immunoreactivity used gain set at 2 (Supplementary Fig. 6). Images were adjusted using linear brightness/contrast functions of Adobe Photoshop software. Identification of mouse lumbar spinal cord laminae followed Zeilhofer et al. (2012) and brain regions followed Franklin and Paxinos (1997).

Quantification of Gal₁-mCherry-immunoreactive neuron profiles in 16 µm sections of lumbar L4 and L5 DRG from control unaxotomized animals (*n* = 3) and axotomized animals seven days after axotomy (*n* = 3, ipsilateral; Section 2.3) was as reported, with counting of 6–10 sections and at least 800 profiles per DRG (Holmes et al., 2008).

2.10. Statistical analysis

Statistical significance of real-time quantitative RT-PCR results (Section 2.6) and changes in somatic cell membrane fluorescence after galanin addition (Section 2.8) were judged by two-tailed Student's *t*-test, with *P* values <0.05 considered significant. *P* values of <0.05 and <0.01 are indicated by one and two asterisks, respectively.

2.11. Nomenclature

With respect to nomenclature, the genes *GalR1* and *GalR2* (official symbols, Mouse Genome Informatics Database) encode the gene products Gal₁ and Gal₂ (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=27>), and for convenience transcripts are designated here as Gal₁ and Gal₂ mRNAs.

3. Results

3.1. Generation of *GalR1*-mCherry and *GalR2*-hrGFP knock-in mouse lines

The coding sequences of the fluorescent tags mCherry or hrGFP were cloned in-frame onto the 3' ends of genomic *GalR1* or *GalR2* coding sequences by lambda Red-mediated recombineering, and a smaller subcloned fragment of each was electroporated into embryonic stem (ES) cells (see Materials and methods section; Figs. 1A and 2A, middle panels). Screening of ES cell clones by real-time quantitative genomic PCR resulted in 6/97 *GalR1*-mCherry clones and 10/40 *GalR2*-hrGFP clones with one correctly targeted, knock-in allele and one endogenous allele of the receptor gene. Correct targeting of selected ES cell clones was confirmed further by Southern blot analysis using 5' and 3' probes external to the targeting construct sequence, and internal *neo* probe (Supplementary Figs. 1 and 2). Three heterozygous knock-in ES cell clones of *GalR1*-mCherry or *GalR2*-hrGFP were injected into blastocysts to generate chimeras, from which germline transmission of the knock-in allele was confirmed by PCR genotyping for all three *GalR1*-mCherry lines (33, 63 and 97) and one *GalR2*-hrGFP line (32). Expression of knock-in receptor and *neo* mRNAs in adult DRG was demonstrated by RT-PCR (Supplementary Figs. 3 and 4).

Gene expression can be perturbed by the presence of a nearby *neo* gene under the control of a strong promoter (Ema et al., 2006; Maguire




Fig. 2. Gene-targeting of *GalR2* and genotype analysis. (A) Schematic diagram of endogenous *GalR2* (top panel), knock-in *GalR2*-hrGFP-[*neo*⁺] (middle panel) and knock-in *GalR2*-hrGFP-[Δ *neo*] (bottom panel) alleles. Indicated relative locations are the two exons of *GalR2* (boxed) with coding sequences (CDS; black filled boxes); the downstream terminal exon of *ExoC7* (exocyst complex component 7) on the other DNA strand (box with arrowhead); and restriction sites *Xmn*I (X), *Blp*I (Bl, greytone) and *Bci*VI (B). [*Xmn*I sites are shown as used to characterize the [*neo*⁺] allele (Supplementary Fig. 2).] The knock-in *GalR2*-hrGFP-[*neo*⁺] DNA (middle panel) includes the targeting construct (grey horizontal thickened line), and the 3' end of the *GalR2* CDS (exon 2) joined to knock-in elements as in Fig. 1A except for exchanging hrGFP (diagonal banded box; hrGFP protein sequence AAK63811) for mCherry. Locations of external 5' and 3' probes, *neo* probe, and hybridizing DNA fragments are also shown (see Supplementary Fig. 2A for more detailed image of [*neo*⁺] allele). Note that in the *GalR2*-hrGFP-[Δ *neo*] knock-in allele (bottom panel) the SV40-*neo* cassette flanked by FRT sites has been removed by FLPe. (B) Southern blot analysis of tail DNA from wild-type (W) and *GalR2*-hrGFP-[Δ *neo*] knock-in line 32 (K) mice validates correct insertion of the targeting constructs. DNA was digested and hybridized with: *Bci*VI and *GalR2* 5' external probe (left panel; W: 5366 bp, K: 6664 bp); *Blp*I and *GalR2* 3' external probe (middle panel; W: 5466 bp, K: 6767 bp); and *Bci*VI and *neo* probe, which only hybridized to positive-control heterozygous *GalR2*-hrGFP-[*neo*⁺] ES cell clone 32 (right panel; lane N: 1653 bp). DNA ladder as Fig. 1B.

et al., 2014; Revell et al., 2005), so the downstream SV40-*neo* cassette selection marker flanked by FRT (FLP recombination target) sites (Figs. 1A and 2A, middle panels) was excised *in vivo* by crossing with *ACTB:FLPe* transgenic mice in which FLPe recombinase is under the direction of the human β -actin promoter (Buchholz et al., 1998; Rodriguez et al., 2000). Animals heterozygous for *GalR1*-mCherry, negative for *neo*, and positive for deletion of the SV40-*neo* cassette (Δ *neo*) by PCR genotyping were inbred to produce homozygous *GalR1*-mCherry-[Δ *neo*] knock-in mice (lines 33 and 97), and the corresponding strategy was used to produce homozygous *GalR2*-hrGFP-[Δ *neo*] knock-in mice (see Materials and methods section). DNA sequencing of Δ *neo* PCR genotyping products confirmed that FLPe had precisely excised the SV40-*neo* cassette resulting in a product with a single remaining recombined FRT site (Figs. 1A and 2A, bottom panels), while Southern blot analysis confirmed both the expected different restriction fragment sizes of knock-in compared to endogenous alleles and the absence of *neo*-hybridizing sequences in *GalR1*-mCherry lines 33 (Fig. 1B) and 97 (data not shown), and in the *GalR2*-hrGFP knock-in (Fig. 2B).

3.2. mRNA expression in DRG from knock-in mice

Expression and correct splicing of transcripts from the knock-in genes was assessed by RT-PCR of adult DRG, the *GalR1* and *GalR2* genes having respectively three and two exons (Pang et al., 1998; Wang et al., 1997). *GalR1*-mCherry line 33 expressed the expected spliced product of *GalR1* exons 1–3 fused to mCherry coding sequence (637 bp), mCherry to the heterologous 3'-UTR (431 bp), and did not express *neo* (Supplementary Fig. 3). Similar results were obtained for *GalR1*-mCherry line 97 (data not shown) which was therefore discontinued. The *GalR2*-hrGFP knock-in expressed the spliced product of coding sequences from *GalR2* exons 1–2 (426 bp), both *GalR2* fused to hrGFP (533 bp) and hrGFP to the heterologous 3'-UTR (483 bp), and did not express *neo* (Supplementary Fig. 4). The identities of knock-in RT-PCR products were confirmed by DNA sequencing, and it is important to note that products that did not span exons were shown to be RT-

dependent i.e. derived from mRNA and not genomic DNA contamination (Supplementary Figs. 3 and 4).

Quantitative RT-PCR was used to determine whether expression levels of the knock-in mRNA either differed from wild-type mouse endogenous receptor or led to adaptive regulation of galanin and galanin receptor mRNAs (Hawes et al., 2005; Hohmann et al., 2003). Expression levels in DRG from five individual wild-type, *GalR1*-mCherry knock-in or *GalR2*-hrGFP knock-in mice were compared using previously published assays for *Gal*₁, *Gal*₂ and galanin spliced coding sequences (Hobson et al., 2006) that are common to both the wild-type and knock-in animals. We have reported previously that *Gal*₃ mRNA expression in mouse DRG is too low for reliable comparisons (Hobson et al., 2006). Compared to wild-type mice, there were no significant differences in the levels of *Gal*₁ or galanin mRNAs detected in either *GalR1*-mCherry knock-in (0.856 ± 0.177 , $P = 0.165$ and 0.904 ± 0.072 , $P = 0.477$, respectively) or *GalR2*-hrGFP knock-in mice (1.261 ± 0.099 , $P = 0.067$ and 1.102 ± 0.195 , $P = 0.850$, respectively). In contrast, levels of *Gal*₂ mRNA varied depending on genotype, with a small but significant increase in *GalR1*-mCherry knock-ins (1.361 ± 0.076 , $P = 0.020$; $*P < 0.05$) and a significant decrease in *GalR2*-hrGFP knock-ins (0.524 ± 0.080 , $P = 0.004$; $**P < 0.01$).

The quantitative RT-PCR results were also used to compare the relative abundance of different transcripts (Marsh et al., 2012; Pollema-Mays et al., 2013). In wild-type DRG *Gal*₁ and *Gal*₂ mRNAs were amplified to detectable levels (mean threshold cycle, C_t) at respectively 25.37 and 32.58 cycles (each $n = 5$), the difference of 7.21 cycles corresponding to *Gal*₂ being 148-fold less highly expressed than *Gal*₁. These comparatively low expression levels of *Gal*₂ mRNA were RT-dependent, i.e. derived from mRNA, as no products were detected in RT-minus controls at 50 cycles.

3.3. Live-cell imaging of *Gal*₁-mCherry and *Gal*₂-hrGFP proteins in primary DRG neurons from knock-in mice

In preliminary experiments to detect mCherry or hrGFP fluorescence by confocal microscopy, the PC12 cell line was transiently transfected

with either human (h) Gal₁-mCherry or hGal₂-hrGFP cDNAs under the control of the strong CMV (cytomegalovirus) promoter/enhancer (data not shown). Imaging conditions were then established for detecting the much lower fluorescence of each knock-in gene product under the control of the endogenous promoter in primary DRG neurons (Materials and methods section). Cells were detected that expressed a wide range of different levels of Gal₁-mCherry fluorescence associated with the somatic cell membrane (Fig. 3A, middle row). However, under these sensitive detection conditions the globular, intracellular autofluorescence from lipofuscin (see Discussion section; Terman and Brunk, 2004) was also readily apparent within the cell bodies of both knock-in and wild-type neurons, which made it impossible to distinguish between specific Gal₁-mCherry fluorescence and non-specific lipofuscin autofluorescence within the neuronal cell bodies (Schnell

et al., 1999). Growth cones were also examined, as lipofuscin is limited to the neuronal cell body (Gorenstein and Ribak, 1985), but Gal₁-mCherry fluorescence was not detected.

Gal₂-hrGFP fluorescence was expected to be more difficult to detect than Gal₁-mCherry, due to the much lower mRNA expression (see above, Section 3.2). Gal₂-hrGFP fluorescence at the somatic cell membrane was near the limits of detection, but was detectable in 3 of 150 DRG neurons analysed (Fig. 3B).

A previous study in transfected CHO cells demonstrated a decrease in fluorescently-tagged Gal₁ receptor at the cell membrane following incubation with 100 nM–2 μM galanin (Wirz et al., 2005). To study the effect of galanin on Gal₁-mCherry localization in primary DRG neurons, cells with comparatively high somatic cell membrane fluorescence were selected and imaged at 37 °C in a recently available medium




Fig. 3. Detection of Gal₁-mCherry and Gal₂-hrGFP fluorescence by live-cell imaging. (A) Primary DRG neurons from Gal₁-mCherry knock-in (cells 1–5) or wild-type (wt) mice are shown in brightfield images (top row); corresponding original fluorescent images, each acquired during the same imaging session with identical confocal settings (middle row); and corresponding adjusted images to emphasize somatic cell membrane fluorescence (see Materials and methods section), with cells 4, 5 and wt images treated identically (bottom row). Note that both knock-in and wild-type cells have intracellular autofluorescence within the neuronal cell body due to lipofuscin, but only knock-in cells have somatic cell membrane fluorescence. (B) Primary DRG neurons from Gal₂-hrGFP knock-in (cells 1–3) or wild-type (wt1–3) mice are shown in brightfield images (top row); corresponding adjusted confocal fluorescent images (second row); corresponding brighter images to emphasize somatic cell membrane fluorescence (third row); and magnified fluorescent images from knock-in cells 1–3 at each of the two relative brightness levels (areas boxed in second and third rows), with arrows indicating the position of somatic cell membranes (bottom row). Knock-in and wild-type cells from the same imaging sessions are shown (1/wt1, 2/wt2 or 3/wt3). Note that expression of Gal₂-hrGFP fluorescence at the somatic cell membrane is at the limits of detection, and that both knock-in and wild-type cells have intracellular autofluorescence within the cell body due to lipofuscin. For (A) and (B), each fluorescent image is a single optical section from a z stack, and the scale bar is 5 μm.

with reduced background fluorescence (Materials and methods section). In control Gal₁-mCherry neurons there was no significant decrease in somatic cell membrane fluorescence on re-imaging at 20 min, i.e. no apparent photo-bleaching, whereas the somatic cell membrane fluorescence significantly decreased by 35% in neurons re-imaged 20 min after the addition of 1 μM galanin ($65.17 \pm 5.18\%$; $P = 0.0067$; Fig. 4), demonstrating agonist-induced internalization.

3.4. Immunohistochemical detection of Gal₁-mCherry protein in DRG, spinal cord and brain of adult knock-in mice

In order to detect Gal₁-mCherry protein expression with higher sensitivity, we used a previously characterized antibody to mCherry (Erbs et al., 2015; Voigt et al., 2012) that specifically detected the protein expressed from CMV-driven hGal₁-mCherry cDNA in transiently transfected PC12 cells (data not shown). Gal₁-mCherry immunofluorescence in adult lumbar DRG was detected as comparatively high expression in a restricted subset of neurons (Fig. 5A–C, I), with localization to the somatic cell membrane and a punctate distribution within the cytoplasm (Fig. 5E–H, J), whereas in neurons with lesser immunofluorescence localization to the cell surface was often not detected (Fig. 5K–L). In wild-type DRG specific immunofluorescence was not apparent (Fig. 5D). Previously we reported quantitative RT-PCR results showing that Gal₁ mRNA decreased by 37% in wild-type mouse DRG seven days after sciatic nerve transection (axotomy; Hobson et al., 2006), whereas here by cell counts of Gal₁-mCherry immunoreactive neuronal profiles no apparent difference was detected between $10.9 \pm 1.9\%$ in control lumbar L4 and L5 DRG and $9.5 \pm 1.1\%$ in ipsilateral L4 and L5 DRG seven days after axotomy (each $n = 3$, \pm SEM).

Within adult lumbar spinal cord, high levels of Gal₁-mCherry immunofluorescence were detected in the superficial layers of the dorsal horn in lamina I–II processes, with lesser levels in the lateral spinal nucleus (LSN) and around the central canal in lamina X (Fig. 6A–C). Little immunofluorescence was detected in the ventral horn (Fig. 6D), and specific immunofluorescence was not detected in wild-type cord (Supplementary Fig. 5). Occasional intrinsic cell bodies were detected in lamina I/II, the lamina III/IV border and lamina X (boxed, Fig. 6E, G and H; Supplementary Fig. 5), the most highly expressing cells showing somatic cell membrane localization and puncta within the cell bodies (Fig. 6I–M). Outward transport of Gal₁-mCherry from the cell body was detected as puncta within cell processes of multipolar neurons within the lamina

III/IV border area (Fig. 6J), with further sections in Supplementary Fig. 5–J). In addition, we show a neuron within the medial part of lamina IV (Zeilhofer et al., 2012) extending a process laterally ~75 μm to end in a terminal containing multiple Gal₁-mCherry immunofluorescent puncta, apposed to another Gal₁-mCherry expressing neuron (Fig. 6N–P).

In wild-type brain no specific immunofluorescence was detected, whereas in similar sections of knock-in brain high levels of Gal₁-mCherry immunoreactivity were detected within thalamus, hypothalamus and amygdala (Fig. 7A and B). Examples of the most immunoreactive brain regions are shown at higher magnification (5×), including the intermediate and ventral parts of the lateral septal nucleus (Fig. 7C and D); a number of thalamic nuclei including the paraventricular thalamic nucleus (Fig. 7E and F); the dorsomedial and ventromedial hypothalamic nuclei and median eminence (Fig. 7G); medial amygdala nuclei (Fig. 7H); and the locus coeruleus (Fig. 7I). Confocal images at higher magnification show localization of Gal₁-mCherry to the somatic cell membrane of neurons within the lateral septal nucleus (Fig. 7J), high levels of expression in nerve endings within the external zone of the median eminence (Fig. 7K and L) and numerous nerve fibres in the locus coeruleus area (Fig. 7M).

Examples of brain regions with lesser Gal₁-mCherry immunoreactivity (Materials and Methods) are shown in Supplementary Fig. 6. These include the mediocaudal part of the lateral posterior thalamic nucleus; pretectal nucleus; subiculum; medial mammillary nucleus; periaqueductal grey; posteromedial hippocampal amygdala; scattered cells in the ventral-most hippocampal pyramidal cell layer; the ventral part of the dorsal raphe nucleus and medial raphe nucleus. The correspondence of the higher magnification images (Fig. 7 and Supplementary Fig. 6) to those at a lower magnification are shown in Supplementary Fig. 7, which also localize Gal₁-mCherry immunoreactivity in the anterior hypothalamic area and anterior part of basomedial amygdala (Supplementary Fig. 7).

3.5. Absence of immunohistochemical detection of Gal₂-hrGFP protein in adult knock-in mouse tissues

A previously characterized antibody to hrGFP (Sakata et al., 2009; Zhang et al., 2013) specifically detected the protein expressed by CMV-driven hGal₂-hrGFP cDNA in transiently transfected PC12 cells (data not shown). However, we could not detect specific Gal₂-hrGFP protein expression by immunohistochemistry in adult normal DRG,




Fig. 4. Live-cell imaging of changes in Gal₁-mCherry fluorescence at the somatic cell membrane following the addition of galanin. (A) Primary DRG neuron '1' from Gal₁-mCherry knock-in mouse shown (left to right) in brightfield image; corresponding original confocal fluorescent images at time zero and at 20 min after addition of 1 μM galanin (+gal), from which quantifications in (D) were made; and the same fluorescent images adjusted to emphasize cell membrane fluorescence (see Materials and methods section). (B) Corresponding images of primary DRG neuron '2'. (C) Magnified fluorescent images of each cell at both timepoints (areas boxed in (A) and (B)), with arrows indicating the position of somatic cell membranes. Each fluorescent image is a single optical section, and the scale bar ((A) and (B)) is 5 μm. (D) Quantification of changes in Gal₁-mCherry fluorescence at the somatic cell membrane. Compared to somatic cell membrane fluorescence at time zero, defined as 100%, there was not a significant decrease in somatic cell membrane fluorescence in control neurons re-imaging 20 min later (left; $91.75 \pm 3.76\%$, $n = 4$; $P = 0.1155$). In other cells imaged and then re-imaged 20 min after 1 μM galanin addition, there was a significant decrease in somatic cell membrane fluorescence to $65.17 \pm 5.18\%$ (right; $n = 4$; $P = 0.0067$; **, $P < 0.01$). The somatic cell membrane fluorescence at the 20 min timepoint also is significantly decreased in galanin-treated compared to control neurons ($n = 4$; $P = 0.0089$; **, $P < 0.01$).




Fig. 5. Detection of Gal₁-mCherry immunofluorescence in DRG. (A–C) Three confocal images of adult Gal₁-mCherry knock-in lumbar DRG show some neurons with comparatively high immunofluorescence (green colour, boxed) and others with lesser immunofluorescence whereas, (D) in adult wild-type (wt) DRG specific immunofluorescence is not detected (40× objective, scale bar 40 μm). (E–H) Higher magnification images of highly immunofluorescent neurons (boxed in (A–C)) show localization of Gal₁-mCherry to the somatic cell membrane and a punctate distribution within the cytoplasm (40× objective, zoom 6×; scale bar 15 μm). (I) In a confocal image with high, moderate and low level immunofluorescent cells (boxed; scale bar 40 μm), at higher magnification somatic cell membrane localization is apparent in the high expressing neuron (J) but not in either a moderate (K, top) or two low expressing neurons (K bottom and L; scale bar 15 μm). Each fluorescent image is a single optical section from a z stack.

spinal cord or brain, or in DRG and spinal cord after sciatic nerve axotomy which markedly induces Gal₂ mRNA in rat ventral horn motoneurons (Brumovsky et al., 2006b). Immunofluorescence did not differ from wild-type tissue using a range of primary antibody dilutions (Materials and Methods), and omission of the primary antibody eliminated fluorescence. The inability to detect Gal₂-hrGFP is compatible with the low endogenous expression of Gal₂/Gal₂-hrGFP mRNA (Section 3.2; see Discussion section).

4. Discussion

The goal of this study was to produce knock-in mice expressing fluorescently-tagged Gal₁ or Gal₂ receptors for live-cell functional imaging and immunohistochemical localization studies. The Gal₁-mCherry and Gal₂-hrGFP mRNAs were each expressed and correctly spliced in adult DRG from the respective knock-in mice, but the steady-state levels of Gal₂-hrGFP mRNA were decreased by ~50% compared to the endogenous Gal₂ transcript of wild-type DRG. This may be due to the presence of mRNA stabilization sequence(s) present in the endogenous Gal₂ mRNA 3'-UTR that do not occur in the heterologous 3'-UTR of Gal₂-hrGFP mRNA (Fig. 2A), such as the stabilization motif CCTnCCCTG-like sequence ACTACCTG (Cohen et al., 2014; NM_010254).

The live-cell imaging of Gal₁-mCherry and Gal₂-hrGFP proteins was restricted to the somatic cell membrane, axons and growth cones due to lipofuscin autofluorescence within the soma (see below). This still allowed the detection of Gal₁-mCherry fluorescence localized to the somatic cell membrane, plus the demonstration of galanin-dependent internalization in DRG neurons. Previously, [¹²⁵I]-galanin binding to neuronal cell bodies of intact monkey DRG or human nodose ganglion (Sweerts et al., 2000; Zhang et al., 1995b), lacked the spatial resolution

to distinguish cell membrane from intracellular binding, whereas the increased membrane excitability upon addition of galanin to acutely dissociated rat DRG neurons indicated functional receptor(s) localized to the somatic cell membrane (Kerekes et al., 2003). Intact DRG neuron cell bodies have been shown to express surface receptors for a variety of neuroactive substances e.g. the GPCRs neuropeptide Y (NPY) type Y1 receptor (Y1-R) and somatostatin type 2A receptor (Sstr2A) (Hanani, 2005; Shi et al., 2014; Zhang et al., 1994).

Lipofuscin autofluorescence is known to complicate fluorescent microscopy of brain, spinal cord and DRG (Schnell et al., 1999), for example identifying GFP-GR (glucocorticoid receptor) knock-in expression in brain (Usuku et al., 2005), and will be exaggerated by the very sensitive detection conditions used here (Spitzer et al., 2011; Materials and methods section). Lipofuscin is composed of oxidized protein and lipid degradation residues, that is located within lysosomes but cannot be degraded by lysosomal hydrolases and so accumulates over time within post-mitotic cells such as neurons or cardiac myocytes (Sulzer et al., 2008; Terman and Brunk, 2004). Studies on lipofuscin generally focus on aged animals, but it has been reported in 2 month old rat brain and heart (Ikeda et al., 1985; Nakano et al., 1995; Sulzer et al., 2008), and in 6 week old brain and 1–3 month old spinal cord from mouse (Bandyopadhyay et al., 2014; Constantinides et al., 1986; Usuku et al., 2005). The classical defining characteristic of lipofuscin is broad spectrum autofluorescence (Eldred et al., 1982; Sulzer et al., 2008), as we detected in 500–700 nm emission spectral scans of wild-type DRG neurons (data not shown), which overlaps the commonly used fluorophores such as mCherry and hrGFP with emission peaks of respectively 610 and 506 nm (Shaner et al., 2004; Stratagene-Agilent).

Gal₁-mCherry protein was localized within DRG, spinal cord and brain using the higher sensitivity of immunohistochemistry (Figs. 5–7).




Fig. 6. Detection of Gal₁-mCherry immunofluorescence in spinal cord. (A) Low-power photomicrograph (10× objective) and (B–D) confocal images (20× objective) of adult *GalR1*-mCherry knock-in lumbar spinal cord showing high levels of immunofluorescence in the superficial dorsal horn laminae I–II, with lesser levels in the lateral spinal nucleus (LSN, labelled 'L') and around the central canal (white asterisk) in lamina X (A–C), whereas little immunofluorescence was detected in the ventral horn (D). (E–H) Higher magnified confocal images (40× objective) of mid superficial dorsal horn (E); lateral superficial dorsal horn and LSN (labelled 'L'; F); lamina III/IV border (G); and lamina X (H; central canal, white asterisk); with examples of local cell bodies boxed. (I–L, M) Higher magnification confocal images (40× objective, zoom 6×) of local neurons (boxed in row above) show distinct somatic cell membrane localization in highly fluorescent cells of the superficial dorsal horn (I), lamina III/IV border (J) and lamina X (M; location arrowed in N, mainly different plane), whereas in less fluorescent neurons cell surface localization may (K, arrow; insert merged 3 z-sections) or may not be detected (K–L; L, merged 4 z-sections). Note the multiple Gal₁-mCherry immunofluorescent puncta within neuronal processes (J, arrows; additional images in Supplementary Fig. 5A–F), and insert of M shows three main neuronal projections (each double arrows; merged 16 z-sections, 1 μm intervals). (N–P) Confocal images of medial spinal cord including a lamina IV neuron sending a process laterally to another Gal₁-mCherry expressing neuron (boxed, N; 40× objective); as shown at higher magnification to show the neuronal process (O; objective 40×, zoom 3×; merged 8 z-sections, 1 μm intervals), with insert images showing somatic cell membrane localization of each cell (right cell, merged 3 z-sections); and at further magnification Gal₁-mCherry puncta are seen in the terminal process of the lamina IV neuron (arrows, P; objective 40×, zoom 8×; merged 7 z-sections, 1 μm intervals), with insert images of details from successive z-sections of the terminal process. FD is funiculus dorsalis. Each confocal image is a single optical section from a z stack unless indicated, with (B–D) at same brightness intensity, as are (E–H and N). Scale bars: 150 μm for 20× objective; 70 μm for 40× objective; 40 μm for 40× objective with zoom 3×; and 15 μm for 40× objective with either zoom 6× or 8×.

Similarly, in the δ -opioid receptor (DOR)-EGFP knock-in mouse fluorescence was often weak and required EGFP-specific antibodies for proper visualization (Erbs et al., 2015), and DOR and Gal₁ mRNA are expressed at similar levels in mouse DRG based on next generation RNA sequencing (RNA-Seq; Supplementary Table 1 of Thakur et al., 2014). Cellular localization of a specific GPCR can differ between different regions of the nervous system, for example DOR-EGFP is localized to the somatic cell membrane in DRG but is not readily detected at the cell surface of spinal cord neurons (Ceredig and Massotte, 2014; Erbs et al., 2015; Nathanson, 2008). In highly immunofluorescent Gal₁-mCherry neurons, somatic cell membrane localization was detected in DRG (Fig. 5E–H, J), in spinal cord lamina I/II, lamina III/IV border, medial lamina IV and lamina X (Fig. 6I–K, M and O; Supplementary Fig. 5) and within brain in the lateral septal nucleus and locus coeruleus (Fig. 7J and M). In the live-cell

imaging of primary DRG neurons we did not detect Gal₁-mCherry fluorescence in growth cones or axons, which could be clearly viewed because lipofuscin autofluorescence is limited to the neuronal cell body (Gorenstein and Ribak, 1985). In contrast, the combination of the immunohistochemistry and the generally restricted expression among intrinsic spinal cord neurons allowed the detection of Gal₁-mCherry transport within cell processes as puncta in successive confocal images of neurons within the lamina III/IV border area (Fig. 6J and Supplementary Fig. 5–J) and medial lamina IV (Fig. 6N–P; Zeilhofer et al., 2012).

Previously, we detected Gal₁ mRNA in mouse DRG by RT-PCR (Hobson et al., 2006), and here detected Gal₁-mCherry immunofluorescence in a restricted subset of neurons (Fig. 5A–C, I) corresponding to 10.9% of lumbar L4 and L5 neuronal profiles. Published data on Gal₁ mRNA + neuron profiles is not available for mouse DRG, but in adult




Fig. 7. Detection of Gal₁-mCherry immunofluorescence in brain. (A–B) In low-power micrographs (2.5×), specific immunofluorescence is not detected in adult wild-type (wt) brain (A), whereas in a similar section of adult Gal₁-mCherry knock-in brain, high levels of Gal₁-mCherry immunoreactivity were detected (B; see F–H for same section at higher magnifications). (C–I) Higher magnification images (5×) show high immunoreactivity in: (C) intermediate and ventral parts of lateral septal nuclei (LSI, LSV) and scattered cells within caudate putamen (CPu), but not in the dorsal part of the lateral septal nucleus (LSD) at this level or in medial septal nucleus (MS); (D) LSI, and scattered cells within CPu; (E–F) paraventricular-, medial mediodorsal-, central medial-, paracentral-, central lateral- and intermediodorsal-thalamic nuclei (PV; MDM; CM; PC; CL; IMD), but not in dentate gyrus (DG) or medial habenula (MHb); (G) dorsomedial and ventromedial hypothalamic nuclei (DM; VMH), median eminence (ME; see below) and scattered cells within posterior and lateral hypothalamic areas (PH; LH); (H) posterior basomedial and posterodorsal medial amygdala nuclei (BMP; MePD) and LH; (I) locus coeruleus (LC) and posterodorsal tegmental nucleus (PDTg), but not cerebellum (CB). (J–M) Confocal images at higher magnification (J–L: 40×; M: 40×, zoom 3×; scale bars 40 μm) showing: (J) somatic cell membrane localization in some neurons within the intermediate part of the lateral septal nucleus (LSI; arrows; area boxed in (D)); (K) high levels of expression in median eminence (ME) shown either over-bright to show location of third ventricle (3V; left pair of arrows showing join of torn tissue; 30 z-sections) or less-bright image (L; 3 z-sections), with insert of boxed area magnified to show immunoreactive fibres and an absence of immunoreactive cell bodies (40×, zoom 6×; scale bar 15 μm; 3 z-sections); and (M) fibres within the locus coeruleus (LC) area, together with a single cell body (arrow; 20 z-sections), with inserts showing somatic cell membrane localization (single z-sections). Other abbreviations: aca, anterior part of anterior commissure; and 4V, 4th ventricle. Images (A–B) and (C–I) are each at the same brightness intensity, with scale bars of 1 mm (A–B, 2.5× objective) or 0.5 mm (C–I, 5× objective lens). Sections are similar to mouse brain atlas Figures 46 (A, B), 23 (C), 29 (D, J), 40 (E), 46 (F–H, K, L) and 79 (I, M) of Franklin and Paxinos (1997).

rat DRG the initial figure was 23% whereas in a more sensitive study using labelled riboprobes the figure was 51% (Kerekes et al., 2003; O'Donnell et al., 1999; Xu et al., 1996). Differences between mouse and rat DRG neuron profiles are not uncommon, for example between 7 and 20% for NPY receptor Y1 mRNA + or between 39 and 8% for P2X5 immunopositive profiles (Shi et al., 1998; Zeng et al., 2013). In addition, immunohistochemical analysis can give lower numbers of positive neurons compared to ISH, as for example with DOR-EGFP immunostaining compared to DOR mRNA ISH in mouse DRG (Scherrer et al., 2009; Wang et al., 2010). The apparent lack of effect of axotomy on Gal₁-mCherry immunoreactive neuronal profiles (9.5% versus control 10.9%), in combination with our previous quantitative RT-PCR results showing a 37% decrease in Gal₁ mRNA in wild-type DRG

(Hobson et al., 2006), may be explained in part by a threshold for immunoreactive detection. If the mRNA decrease occurs mainly in the highly expressing neurons they would still maintain sufficient expression to be counted as Gal₁-mCherry immunopositive. Consistent with this, an ISH study of NPY mRNA expression in rat superior cervical ganglion (SCG) after axotomy detected a 40% decrease in average grain density/neuron, but the number of NPY mRNA + neurons was unchanged (Kroesen et al., 1997).

In DRG the potential sources of galanin to bind to somatic cell membrane Gal₁ are either via fenestrated capillaries that allow access into the neuronal extracellular space (Hanani, 2005) or locally produced ligand. Basal expression of galanin mRNA and protein in DRG are low but increase dramatically after axotomy (Villar et al., 1989; Zhang

et al., 1995a), when it is abundant in the Golgi region and also present stored in large dense-core vesicles within the cell body (Zhang et al., 1995a). Somatic exocytosis of galanin has yet to be studied, though it has been demonstrated for substance P (SP) and calcitonin gene-related peptide (CGRP) (Liu et al., 2011; Trueta and De-Miguel, 2012) and references therein), and in addition to post-axotomy would also be relevant following galanin induction in several other neuropathic pain models (Lang et al., 2015) and during nerve regeneration following nerve crush injury (Villar et al., 1989).

In mouse spinal cord expression of Gal₁ mRNA has previously been detected by northern blot and RT-PCR (Jacoby et al., 2002; Wang et al., 1997), and by ISH was reported as enriched in the dorsal horn (Table 1 of Guo et al., 2012). We detected dense Gal₁-mCherry immunofluorescence in the superficial dorsal horn laminae I–II with lesser levels in the lateral spinal nucleus and lamina X, similar to previous rat Gal₁ mRNA ISH studies (Brumovsky et al., 2006b; O'Donnell et al., 1999). It will be of interest to determine the expression of other neurochemical markers within intrinsic neurons highly expressing Gal₁-mCherry. For example, the potential relationship of the multipolar neurons of the lamina III/IV border (Fig. 6G and J; Supplementary Fig. 5) to the occasional multipolar neurons of similar location that express galanin, NPY receptor Y1-R or somatostatin receptor Sstr2 (Brumovsky et al., 2006a; Melander et al., 1986; Shi et al., 2014), and the relationship of neurons lateral to the central canal and potentially interacting medial lamina IV neurons (Fig. 6M–P) to galanin or Y1R expressing cells (Brumovsky et al., 2006a; Ch'ng et al., 1985; Melander et al., 1986).

The heterogeneous distribution of Gal₁ mRNA in mouse forebrain has been determined by ISH (Hohmann et al., 2003) and was highly similar to [¹²⁵I]-galanin binding sites, which were not detected in mice deficient for Gal₁ (Jungnickel and Gundlach, 2005). The examples of brain regions shown as the most Gal₁-mCherry immunoreactive (Fig. 7 and Supplementary Fig. 7) correspond, with three exceptions, to areas expressing Gal₁ mRNA which on an intensity scale of + to +++++ (from weak to very dense) were in the range of ++ to +++++ (Hohmann et al., 2003). The ISH study did not extend caudally to the locus coeruleus and posterodorsal tegmental nucleus (Fig. 7I) which are known to bind [¹²⁵I]-galanin (Jungnickel and Gundlach, 2005), so the apparent discrepancy is in median eminence (ME) between the high level of Gal₁-mCherry immunofluorescence (Fig. 7G, K and L) and the absence of Gal₁ mRNA expression in both mouse and rat (Fig. 4d of Hohmann et al., 2003; Mitchell et al., 1997). However, Gal₁ mRNA is detected in most hypothalamic nuclei that project towards it, and as there is a high density of [¹²⁵I]-galanin binding sites in the ME of mouse and rat (Jungnickel and Gundlach, 2005), these findings are therefore compatible with the hypothesis that median eminence Gal₁ receptors are transported and play a local role at the nerve terminals (Mitchell et al., 1997). This is now clearly demonstrated by Gal₁-mCherry immunofluorescence localized to densely packed nerve endings within the external zone of the ME (Fig. 7K–L), a blood–brain barrier-free circumventricular organ (Fekete and Lechan, 2014; Mullier et al., 2010) with a very high density of galanin-immunoreactive fibres in both mouse and rat (Melander et al., 1986; Perez et al., 2001).

Brain regions with lesser Gal₁-mCherry immunoreactivity (Materials and methods section; Supplementary Fig. 6) correspond to Gal₁ mRNA intensities in the range + to ++ (Hohmann et al., 2003), or in the case of the lateral posterior thalamic nucleus is known to bind [¹²⁵I]-galanin (Jungnickel and Gundlach, 2005), while the dorsal raphe nucleus (DR) and median raphe nucleus were too caudal to be included in the ISH study. Gal₁ mRNA is expressed in adult rat DR (Burazin et al., 2000; O'Donnell et al., 1999), but on the basis of a lack of Gal₁-immunoreactivity or detection of Gal₁ mRNA by ISH in mouse, a species difference in expression was proposed (Larm et al., 2003). Since then, [¹²⁵I]-galanin binding sites and weak expression of Gal₁ mRNA in the ventral part of mouse DR have been detected (Borroto-Escuela et al., 2010; Jungnickel and Gundlach, 2005). Here we show Gal₁-mCherry immunoreactivity in the DR (Supplementary

Fig. 6), galanin receptor agonists having implicated mouse DR Gal₁ in facilitating limbic seizures (Mazarati et al., 2005).

The difficulty in detecting Gal₂-hrGFP fluorescence in the somatic cell membrane of DRG neurons can mainly be ascribed to comparatively low mRNA expression from the endogenous promoter. In wild-type mouse DRG the endogenous Gal₂ mRNA was 148-fold less highly expressed than Gal₁ (Section 3.2), which is consistent with data used in our previous report (Hobson et al., 2006) in which Gal₂ was 136-fold less highly expressed (difference of 7.09 cycles; each $n = 5$). This wide difference in expression of the two receptors is confirmed by RNA-Seq data of adult mouse DRG in which Gal₁ and Gal₂ had FPKM (Fragment Per Kilobase of exon per Million fragments mapped) values of 4.865 and 0.020, respectively (Supplementary Table 1 of Thakur et al., 2014). The expression levels of Gal₂-hrGFP in DRG, spinal cord and brain may be below the sensitivity for detection by immunohistochemistry, but Gal₂ expression appears to be sufficient to affect behaviour. Gal₂-deficient mice have anxiogenic-like and depression-like phenotypes (Bailey et al., 2007; Lu et al., 2008), and compounds with a marked preference for binding Gal₂ over Gal₁ have anticonvulsive and anti-nociceptive activities (Metcalf et al., 2015; Robertson et al., 2010).

Of direct relevance to the very low levels of Gal₂-hrGFP, is the observation that Gal₂ is likely to be under translational control mediated by upstream open reading frames (uORFs) within the 5'-UTR. This will tend to diminish translation of the main ORF by reducing the number of ribosomes reaching and initiating at the main start codon (Barbosa et al., 2013; Calvo et al., 2009). Unlike the 5'-UTR of mouse and rat Gal₁ mRNA sequences that do not contain upstream ATG triplets (NM_008082; NM_012958), those of mouse Gal₂ contains six uORFs (here designated uORF1–6) whilst rat Gal₂ contains only two uORFs (Fig. 8). These latter two are conserved between mouse and rat (hereafter uORF3 and uORF6) in both relative position and approximate length, potentially encoding 5 and 71/69 amino acids respectively, and the mouse/rat uORF6 terminates only 4 nucleotides upstream of the Gal₂ initiation codon. Such proximity has previously been correlated with translational repression of the main coding sequence (Child et al., 1999; Kozak, 1987; but see Calvo et al., 2009), as has uORF length (Calvo et al., 2009; Kozak, 2001), and uORF-mediated repression may or may not depend on the potential uORF-encoded protein sequence (Child et al., 1999; Iacono et al., 2005; Morris and Geballe, 2000) but conservation of the uORF mRNA sequence between species suggests a functional selection (Churbanov et al., 2005; Crowe et al., 2006; Iacono et al., 2005).

Ribosome profiling (ribo-seq) data based on deep-sequencing of ribosome-protected mRNA fragments is not yet available for mouse neurons (Michel et al., 2014), but is for initiating ribosomes of the mouse ES cell line E14 in which Gal₂ has low expression and ribosome density (Ingolia et al., 2011). The predicted initiation site of uORF6 has a ribosome footprint, with a peak density ~1.7-fold higher than at the Gal₂ initiation site (Materials and methods section, Section 2.1; Ingolia et al., 2011; Michel et al., 2014), which suggests a functional role for the conserved uORF6. Intriguingly, endoplasmic reticulum (ER)-stress and a number of other stressors that transiently inhibit the translation of most mRNAs can also promote translation initiation of mRNAs with uORFs (Barbosa et al., 2013; Spriggs et al., 2010), and ER-stress is known to occur in vivo following neuronal axon damage, spinal cord injury or brain trauma (Li et al., 2013; Nakka et al., in press; Yasuda et al., 2014). However, attempts to detect Gal₂-hrGFP protein in DRG or spinal cord at 3 or 7 days after sciatic nerve peripheral axotomy were unsuccessful (Section 3.5). Further studies could be useful either in DRG after carrageenan-induced inflammation when Gal₂ mRNA is induced in rat (Shen Shi et al., 1997) or in the carotid body which has 100-fold more Gal₂ than Gal₁ mRNA in rat (Hawes and Picciotto, 2005; Porzionato et al., 2010). There is now a clear need for in vitro studies on the mechanism of Gal₂ translational control using various stressors (Barbosa et al., 2013; Spriggs et al., 2010) in order to understand both




Fig. 8. Upstream open reading frames (uORFs) are present in mouse and rat Gal₂ mRNA. Alignment of the 5'-UTR sequences of mouse and rat Gal₂ mRNA showing uORFs, with ATG triplets (*bold underlined, red*) and associated ORFs (*bold, green*) upstream of the Gal₂ coding region ('Gal₂'; *bold, blue*) indicated, and note that of the six uORFs in the mouse sequence (uORF1-6) there is conservation of uORF3 and uORF6 in rat. For clarity, the open reading frame of mouse uORF4 is not indicated. Sequences shown are mouse (Mus) and rat mRNA reference sequences (respectively NM_010254 with 5'-UTR of 547 nt, and NM_019172 with 5'-UTR of only 20 nt), with additional rat 5'-UTR sequence derived from expressed sequence tag (EST) CB780446 and further extended by EST CB713787 to 466 nt. The rat sequence shares identity with the predicted rat Gal₂ mRNA sequence (XM_008768432) and rat hypothalamic cDNA clones including 5'-UTRs of 492 and 296 bp have been reported, though the sequences are not available (Howard et al., 1997; U94322). The mouse sequence is supported by cDNAs/ESTs including uORF1-6 (AK053776, BC116980, BB607282), uORF2-6 (BC116982) and uORF5-6 (AK132050, BY712835) isolated from embryonic day 12 embryo or head, neonatal day 0 eyeball, and brain.

the conditions and time-courses of Gal₂ protein expression, preferably in a neuronal-like cell line.

5. Conclusions

The generation and initial characterization of the Gal₁-mCherry knock-in mice will allow more detailed regional tissue distribution studies, co-localization studies, interactome analysis (Bauch et al., 2014) and provide an impetus to understand the function of Gal₁ at the somatic cell membrane. Expression of Gal₂-hrGFP was at the limits of detection and a possible mechanism involving uORFs is discussed.

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.mcn.2015.08.006>.

Competing interests

The authors declare that they have no competing financial interests.

Acknowledgements

This work was supported by the Medical Research Council; Wellcome Trust; Diabetes UK; and the National Institute on Ageing (AG10668). We thank Sarah Munson at Geneta (Dept. of Biochemistry, University of Leicester) for ES cell clones and chimeras; Clare Sims and Peter Gardiner for animal care; Drs. Mark Jepson and Katy Jepson (Wolfson Bioimaging Facility) for advice on live cell imaging; and the

Wolfson Foundation and BBSRC Alert 13 capital grant (BB/L014181/1) for funding the bioimaging facility at Bristol University.

References

Adams, D.J., Quail, M.A., Cox, T., van der Weyden, L., Gorick, B.D., Su, Q., Chan, W.I., Davies, R., Bonfield, J.K., Law, F., Humphray, S., Plumb, B., Liu, P., Rogers, J., Bradley, A., 2005. A genome-wide, end-sequenced 129Sv BAC library resource for targeting vector construction. *Genomics* 86, 753–758.

Anderson, K.L., Sanderson, J., Gerwig, S., Peychl, J., 2006. A new configuration of the Zeiss LSM 510 for simultaneous optical separation of green and red fluorescent protein pairs. *Cytom. A* 69, 920–929.

Bailey, K.R., Pavlova, M.N., Rohde, A.D., Hohmann, J.G., Crawley, J.N., 2007. Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. *Pharmacol. Biochem. Behav.* 86, 8–20.

Balthasar, N., Coppari, R., McMinn, J., Liu, S.M., Lee, C.E., Tang, V., Kenny, C.D., McGovern, R.A., Chua Jr., S.C., Elmquist, J.K., Lowell, B.B., 2004. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. *Neuron* 42, 983–991.

Bandyopadhyay, U., Nagy, M., Fenton, W.A., Horwich, A.L., 2014. Absence of lipofuscin in motor neurons of SOD1-linked ALS mice. *Proc. Natl. Acad. Sci. U. S. A.* 111, 11055–11060.

Barbosa, C., Peixeiro, I., Romao, L., 2013. Gene expression regulation by upstream open reading frames and human disease. *PLoS Genet.* 9, e1003529.

Barreto, S.G., Bazargan, M., Zotti, M., Hussey, D.J., Sukocheva, O.A., Peiris, H., Leong, M., Keating, D.J., Schlothe, A.C., Carati, C.J., Smith, C., Toouli, J., Saccone, G.T., 2011. Galanin receptor 3—a potential target for acute pancreatitis therapy. *Neurogastroenterol. Motil.* 23, e141–e151.

Bauch, C., Koliwer, J., Buck, F., Honck, H.H., Kreienkamp, H.J., 2014. Subcellular sorting of the G-protein coupled mouse somatostatin receptor 5 by a network of PDZ-domain containing proteins. *PLoS One* 9, e88529.

Borroto-Escuela, D.O., Narvaez, M., Marcellino, D., Parrado, C., Narvaez, J.A., Tarakanov, A.O., Agnati, L.F., Diaz-Cabiale, Z., Fuxe, K., 2010. Galanin receptor-1 modulates 5-hydroxytryptamine-1A signaling via heterodimerization. *Biochem. Biophys. Res. Commun.* 393, 767–772.

- Brumovsky, P., Hofstetter, C., Olson, L., Ohning, G., Villar, M., Hokfelt, T., 2006a. The neuropeptide tyrosine Y1R is expressed in interneurons and projection neurons in the dorsal horn and area X of the rat spinal cord. *Neuroscience* 138, 1361–1376.
- Brumovsky, P., Mennicken, F., O'Donnell, D., Hokfelt, T., 2006b. Differential distribution and regulation of galanin receptors-1 and -2 in the rat lumbar spinal cord. *Brain Res.* 1085, 111–120.
- Brunner, S.M., Farzi, A., Locker, F., Holub, B.S., Drexler, M., Reichmann, F., Lang, A.A., Mayr, J.A., Vilches, J.J., Navarro, X., Lang, R., Sperk, G., Holzer, P., Kofler, B., 2014. GAL3 receptor KO mice exhibit an anxiety-like phenotype. *Proc. Natl. Acad. Sci. U. S. A.* 111, 7138–7143.
- Buchholz, F., Angrand, P.O., Stewart, A.F., 1998. Improved properties of FLP recombinase evolved by cycling mutagenesis. *Nat. Biotechnol.* 16, 657–662.
- Burazin, T.C.D., Larm, J.A., Ryan, M.C., Gundlach, A.L., 2000. Galanin-R1 and-R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity. *Eur. J. Neurosci.* 12, 2901–2917.
- Calvo, S.E., Pagliarini, D.J., Mootha, V.K., 2009. Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. *Proc. Natl. Acad. Sci. U. S. A.* 106, 7507–7512.
- Ceredig, R.A., Massotte, D., 2014. Fluorescent knock-in mice to decipher the physiopathological role of G protein-coupled receptors. *Front. Pharmacol.* 5, 289.
- Child, S.J., Miller, M.K., Geballe, A.P., 1999. Translational control by an upstream open reading frame in the HER-2/neu transcript. *J. Biol. Chem.* 274, 24335–24341.
- Ch'ng, J.L., Christofides, N.D., Anand, P., Gibson, S.J., Allen, Y.S., Su, H.C., Tatamoto, K., Morrison, J.F., Polak, J.M., Bloom, S.R., 1985. Distribution of galanin immunoreactivity in the central nervous system and the responses of galanin-containing neuronal pathways to injury. *Neuroscience* 16, 343–354.
- Churbanov, A., Rogozin, I.B., Babenko, V.N., Ali, H., Koonin, E.V., 2005. Evolutionary conservation suggests a regulatory function of AUG triplets in 5'-UTRs of eukaryotic genes. *Nucleic Acids Res.* 33, 5512–5520.
- Cohen, J.E., Lee, P.R., Fields, R.D., 2014. Systematic identification of 3'-UTR regulatory elements in activity-dependent mRNA stability in hippocampal neurons. *Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.* 369.
- Connelly, S., Manley, J.L., 1988. A functional mRNA polyadenylation signal is required for transcription termination by RNA polymerase II. *Genes Dev.* 2, 440–452.
- Constantinides, P., Harkey, M., McClaurry, D., 1986. Prevention of lipofuscin development in neurons by anti-oxidants. *Virchows Arch. A Pathol. Anat. Histopathol.* 409, 583–593.
- Copeland, N.G., Jenkins, N.A., Court, D.L., 2001. Recombinering: a powerful new tool for mouse functional genomics. *Nat. Rev. Genet.* 2, 769–779.
- Cortes, R., Villar, M.J., Verhofstad, A., Hokfelt, T., 1990. Effects of central nervous system lesions on the expression of galanin: a comparative in situ hybridization and immunohistochemical study. *Proc. Natl. Acad. Sci. U. S. A.* 87, 7742–7746.
- Crowe, M.L., Wang, X.Q., Rothnagel, J.A., 2006. Evidence for conservation and selection of upstream open reading frames suggests probable encoding of bioactive peptides. *BMC Genomics* 7, 16.
- Downing, G.J., Battay Jr., J.F., 2004. Technical assessment of the first 20 years of research using mouse embryonic stem cell lines. *Stem Cells* 22, 1168–1180.
- Eldred, G.E., Miller, G.V., Stark, W.S., Feeney-Burns, L., 1982. Lipofuscin: resolution of discrepant fluorescence data. *Science* 216, 757–759.
- Ema, M., Takahashi, S., Rossant, J., 2006. Deletion of the selection cassette, but not cis-acting elements, in targeted Flk1-lacZ allele reveals Flk1 expression in multipotent mesodermal progenitors. *Blood* 107, 111–117.
- Erbs, E., Faget, L., Scherrer, G., Matifas, A., Filliol, D., Vonesch, J.L., Koch, M., Kessler, P., Hentsch, D., Birling, M.C., Koutsourakis, M., Vasseur, L., Veinante, P., Kieffer, B.L., Massotte, D., 2015. A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. *Brain Struct. Funct.* 220, 677–702.
- Fekete, C., Lechan, R.M., 2014. Central regulation of hypothalamic–pituitary–thyroid axis under physiological and pathophysiological conditions. *Endocr. Rev.* 35, 159–194.
- Fink, D., Wohrer, S., Pfeffer, M., Tombe, T., Ong, C.J., Sorensen, P.H., 2010. Ubiquitous expression of the monomeric red fluorescent protein mCherry in transgenic mice. *Genesis* 48, 723–729.
- Franklin, K.B.J., Paxinos, G., 1997. *The Mouse Brain in Stereotaxic Coordinates*. Academic Press, San Diego.
- Gibbs, J.S., Malide, D., Hornung, F., Bennink, J.R., Yewdell, J.W., 2003. The influenza A virus PB1-F2 protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function. *J. Virol.* 77, 7214–7224.
- Gorenstein, C., Ribak, C.E., 1985. Dendritic transport. II. Somatofugal movement of neuronal lysosomes induced by colchicine: evidence for a novel transport system in dendrites. *J. Neurosci.* 5, 2018–2027.
- Guo, Z., Zhao, C., Huang, M., Huang, T., Fan, M., Xie, Z., Chen, Y., Zhao, X., Xia, G., Geng, J., Cheng, L., 2012. Tlx1/3 and Ptf1a control the expression of distinct sets of transmitter and peptide receptor genes in the developing dorsal spinal cord. *J. Neurosci.* 32, 8509–8520.
- Hanani, M., 2005. Satellite glial cells in sensory ganglia: from form to function. *Brain Res. Brain Res. Rev.* 48, 457–476.
- Hawes, J.J., Picciotto, M.R., 2005. Corrigendum: Hawes J.J., Picciotto M.R. 2004. Characterization of GalR1, GalR2, and GalR3 immunoreactivity in catecholaminergic nuclei of the mouse brain. *J. Comp. Neurol.* 479:410–423. *J. Comp. Neurol.* 490, 98–100.
- Hawes, J.J., Brunzell, D.H., Wynick, D., Zachariou, V., Picciotto, M.R., 2005. GalR1, but not GalR2 or GalR3, levels are regulated by galanin signaling in the locus coeruleus through a cyclic AMP-dependent mechanism. *J. Neurochem.* 93, 1168–1176.
- He, B., Counts, S.E., Perez, S.E., Hohmann, J.G., Koprich, J.B., Lipton, J.W., Steiner, R.A., Crawley, J.N., Mufson, E.J., 2005. Ectopic galanin expression and normal galanin receptor 2 and galanin receptor 3 mRNA levels in the forebrain of galanin transgenic mice. *Neuroscience* 133 (2), 371–380.
- Hobson, S.A., Holmes, F.E., Kerr, N.C.H., Pope, R.J., Wynick, D., 2006. Mice deficient for galanin receptor 2 have decreased neurite outgrowth from adult sensory neurons and impaired pain-like behaviour. *J. Neurochem.* 99, 1000–1010.
- Hobson, S.A., Vanderplank, P.A., Pope, R.J., Kerr, N.C., Wynick, D., 2013. Galanin stimulates neurite outgrowth from sensory neurons by inhibition of Cdc42 and Rho GTPases and activation of cofilin. *J. Neurochem.* 127, 199–208.
- Hohmann, J.G., Jurus, A., Teklemichael, D.N., Matsumoto, A.M., Clifton, D.K., Steiner, R.A., 2003. Distribution and regulation of galanin receptor 1 messenger RNA in the forebrain of wild type and galanin-transgenic mice. *Neuroscience* 117, 105–117.
- Holmes, F.E., Arnott, N., Vanderplank, P., Kerr, N.C., Longbrake, E.E., Popovich, P.G., Imai, T., Combadie, C., Murphy, P.M., Wynick, D., 2008. Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour. *J. Neurochem.* 106, 640–649.
- Hooper, M., Hardy, K., Handyside, A., Hunter, S., Monk, M., 1987. HPRT-deficient (Lesch–Nyhan) mouse embryos derived from germline colonization by cultured cells. *Nature* 326, 292–295.
- Howard, A.D., Tan, C., Shiao, L.L., Palyha, O.C., McKee, K.K., Weinberg, D.H., Feighner, S.D., Cascieri, M.A., Smith, R.G., Van der Ploeg, L.H., Sullivan, K.A., 1997. Molecular cloning and characterization of a new receptor for galanin. *FEBS Lett.* 405, 285–290.
- Iacono, M., Mignone, F., Pesole, G., 2005. uAUG and uORFs in human and rodent 5'-untranslated mRNAs. *Gene* 349, 97–105.
- Ikedo, H., Tauchi, H., Sato, T., 1985. Fine structural analysis of lipofuscin in various tissues of rats of different ages. *Mech. Ageing Dev.* 33, 77–93.
- Ingolia, N.T., Lareau, L.F., Weissman, J.S., 2011. Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. *Cell* 147, 789–802.
- Jacoby, A.S., Hort, Y.J., Constantinescu, G., Shine, J., Iismaa, T.P., 2002. Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. *Mol. Brain Res.* 107, 195–200.
- Jungnickel, S.R., Gundlach, A.L., 2005. [(125)I]-Galanin binding in brain of wildtype, and galanin- and GalR1-knockout mice: strain and species differences in GalR1 density and distribution. *Neuroscience* 131, 407–421.
- Kerekes, N., Mennicken, F., O'Donnell, D., Hokfelt, T., Hill, R.H., 2003. Galanin increases membrane excitability and enhances Ca²⁺ currents in adult, acutely dissociated dorsal root ganglion neurons. *Eur. J. Neurosci.* 18 (11), 2957–2966.
- Kerr, N.C.H., Holmes, F.E., Wynick, D., 2004. Novel isoforms of the sodium channels Nav1.8 and Nav1.5 are produced by a conserved mechanism in mouse and rat. *J. Biol. Chem.* 279, 24826–24833.
- Kim, A., Park, T., 2010. Diet-induced obesity regulates the galanin-mediated signaling cascade in the adipose tissue of mice. *Mol. Nutr. Food Res.* 54, 1361–1370.
- Kim, D.K., Yun, S., Son, G.H., Hwang, J.J., Park, C.R., Kim, J.I., Kim, K., Vaudry, H., Seong, J.Y., 2014. Coevolution of the spexin/galanin/kisspeptin family: spexin activates galanin receptor type II and III. *Endocrinology* 155, 1864–1873.
- Kozak, M., 1987. Effects of intergenic length on the efficiency of reinitiation by eucaryotic ribosomes. *Mol. Cell. Biol.* 7, 3438–3445.
- Kozak, M., 2001. Constraints on reinitiation of translation in mammals. *Nucleic Acids Res.* 29, 5226–5232.
- Kroesen, S., Lang, S., Fischer-Colbrie, R., Klimaschewski, L., 1997. Plasticity of neuropeptide Y in the rat superior cervical ganglion in response to nerve lesion. *Neuroscience* 78, 251–258.
- Lang, R., Gundlach, A.L., Holmes, F.E., Hobson, S.A., Wynick, D., Hokfelt, T., Kofler, B., 2015. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. *Pharmacol. Rev.* 67, 118–175.
- Larm, J.A., Shen, P.J., Gundlach, A.L., 2003. Differential galanin receptor-1 and galanin expression by 5-HT neurons in dorsal raphe nucleus of rat and mouse: evidence for species-dependent modulation of serotonin transmission. *Eur. J. Neurosci.* 17, 481–493.
- Lee, E.C., Yu, D., Martinez de Velasco, J., Tessarollo, L., Swing, D.A., Court, D.L., Jenkins, N.A., Copeland, N.G., 2001. A highly efficient *Escherichia coli*-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. *Genomics* 73, 56–65.
- Li, S., Yang, L., Selzer, M.E., Hu, Y., 2013. Neuronal endoplasmic reticulum stress in axon injury and neurodegeneration. *Ann. Neurol.* 74, 768–777.
- Liu, T., Shang, S.J., Liu, B., Wang, C.H., Wang, Y.S., Xiong, W., Zheng, L.H., Zhang, C.X., Zhou, Z., 2011. Two distinct vesicle pools for depolarization-induced exocytosis in somata of dorsal root ganglion neurons. *J. Physiol.* 589, 3507–3515.
- Lobbastael, E., Reumers, V., Ibrahim, A., Paesen, K., Thiry, L., Gijssels, R., Van den Haute, C., Debyser, Z., Baekelandt, V., Taymans, J.M., 2010. Immunohistochemical detection of transgene expression in the brain using small epitope tags. *BMC Biotechnol.* 10, 16.
- Lu, X., Bartfai, T., 2009. Analyzing the validity of GalR1 and GalR2 antibodies using knock-out mice. *Naunyn Schmiedeberg's Arch. Pharmacol.* 379, 417–420.
- Lu, X., Ross, B., Sanchez-Alavez, M., Zorrilla, E.P., Bartfai, T., 2008. Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. *Neuropeptides* 42, 387–397.
- Maguire, S., Estabel, J., Ingham, N., Pearson, S., Ryder, E., Carragher, D.M., Walker, N., Sanger, M.G.P.S.A.P.T., Bussell, J., Chan, W.I., Keane, T.M., Adams, D.J., Scudamore, C.L., Lelliott, C.J., Ramirez-Solis, R., Karp, N.A., Steel, K.P., White, J.K., Gerdin, A.K., 2014. Targeting of Slc25a21 is associated with orofacial defects and otitis media due to disrupted expression of a neighbouring gene. *PLoS One* 9, e91807.
- Marsh, B., Acosta, C., Djouhri, L., Lawson, S.N., 2012. Leak K⁺ channel mRNAs in dorsal root ganglia: relation to inflammation and spontaneous pain behaviour. *Mol. Cell. Neurosci.* 49, 375–386.
- Mazarati, A.M., Baldwin, R.A., Shinmei, S., Sankar, R., 2005. In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures. *J. Neurochem.* 95, 1495–1503.

- Melander, T., Hokfelt, T., Rokaeus, A., 1986. Distribution of galanin like immunoreactivity in the rat central nervous system. *J. Comp. Neurol.* 248, 475–517.
- Metcalf, C.S., Klein, B.D., McDougle, D.R., Zhang, L., Smith, M.D., Bulaj, G., White, H.S., 2015. Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models. *J. Pharmacol. Exp. Ther.* 352, 185–193.
- Michel, A.M., Fox, G., AMK, De Bo, C., O'Connor, P.B., Heaphy, S.M., Mullan, J.P., Donohue, C.A., Higgins, D.G., Baranov, P.V., 2014. GWIPS-viz: development of a ribo-seq genome browser. *Nucleic Acids Res.* 42, D859–D864.
- Mitchell, V., Habertortoli, E., Epelbaum, J., Aubert, J.P., Beauvillain, J.C., 1997. Semiquantitative distribution of galanin-receptor (GAL-R1) mRNA-containing cells in the male rat hypothalamus. *Neuroendocrinology* 66, 160–172.
- Morris, D.R., Geballe, A.P., 2000. Upstream open reading frames as regulators of mRNA translation. *Mol. Cell. Biol.* 20, 8635–8642.
- Mullier, A., Bouret, S.G., Prevot, V., Dehouck, B., 2010. Differential distribution of tight junction proteins suggests a role for tanyocytes in blood-hypothalamus barrier regulation in the adult mouse brain. *J. Comp. Neurol.* 518, 943–962.
- Nakano, M., Oenzil, F., Mizuno, T., Gotoh, S., 1995. Age-related changes in the lipofuscin accumulation of brain and heart. *Gerontology* 41 (Suppl. 2), 69–79.
- Nakka, V.P., Prakash-Babu, P., Vemuganti, R., 2014. Crosstalk between endoplasmic reticulum stress, oxidative stress, and autophagy: potential therapeutic targets for acute CNS injuries. *Mol. Neurobiol.* (in press).
- Nathanson, N.M., 2008. Synthesis, trafficking, and localization of muscarinic acetylcholine receptors. *Pharmacol. Ther.* 119, 33–43.
- O'Donnell, D., Ahmad, S., Wahlstedt, C., Walker, P., 1999. Expression of the novel galanin receptor subtype, GALR2 in the adult rat CNS: distinct distribution from GALR1. *J. Comp. Neurol.* 409, 469–481.
- Page, A.J., Slattery, J.A., Brierley, S.M., Jacoby, A.S., Blackshaw, L.A., 2007. Involvement of galanin receptors 1 and 2 in the modulation of mouse vagal afferent mechanosensitivity. *J. Physiol.* 583, 675–684.
- Pang, L., Hashemi, T., Lee, H.J., Maguire, M., Graziano, M.P., Bayne, M., Hawes, B., Wong, G., Wang, S.K., 1998. The mouse GalR2 galanin receptor: genomic organization, cDNA cloning, and functional characterization. *J. Neurochem.* 71, 2252–2259.
- Parton, L.E., Ye, C.P., Coppari, R., Enriori, P.J., Choi, B., Zhang, C.Y., Xu, C., Vianna, C.R., Balthasar, N., Lee, C.E., Elmquist, J.K., Cowley, M.A., Lowell, B.B., 2007. Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. *Nature* 449, 228–232.
- Perez, S.E., Wymick, D., Steiner, R.A., Mufson, E.J., 2001. Distribution of galaninergic immunoreactive in the brain of the mouse. *J. Comp. Neurol.* 434, 158–185.
- van den Pol, A.N., Yao, Y., Fu, L.Y., Foo, K., Huang, H., Coppari, R., Lowell, B.B., Broberger, C., 2009. Neuropeptide B and gastrin-releasing peptide excite arcuate nucleus neuropeptide Y neurons in a novel transgenic mouse expressing strong *Renilla* green fluorescent protein in NPY neurons. *J. Neurosci.* 29, 4622–4639.
- Pollema-Mays, S.L., Centeno, M.V., Ashford, C.J., Apkarian, A.V., Martina, M., 2013. Expression of background potassium channels in rat DRG is cell-specific and down-regulated in a neuropathic pain model. *Mol. Cell. Neurosci.* 57, 1–9.
- Porzionato, A., Macchi, V., Barzon, L., Masi, G., Belloni, A., Parenti, A., Palu, G., De Caro, R., 2010. Expression and distribution of galanin receptor subtypes in the rat carotid body. *Mol. Med. Rep.* 3, 37–41.
- Revell, P.A., Grossman, W.J., Thomas, D.A., Cao, X., Behl, R., Ratner, J.A., Lu, Z.H., Ley, T.J., 2005. Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions. *J. Immunol.* 174, 2124–2131.
- Robertson, C.R., Scholl, E.A., Pruess, T.H., Green, B.R., White, H.S., Bulaj, G., 2010. Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery. *J. Med. Chem.* 53, 1871–1875.
- Rodriguez, C.I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, A.F., Dymecki, S.M., 2000. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. *Nat. Genet.* 25, 139–140.
- Sakata, I., Nakano, Y., Osborne-Lawrence, S., Rovinsky, S.A., Lee, C.E., Perello, M., Anderson, J.G., Coppari, R., Xiao, G., Lowell, B.B., Elmquist, J.K., Zigman, J.M., 2009. Characterization of a novel ghrelin cell reporter mouse. *Regul. Pept.* 155, 91–98.
- Scherrer, G., Imamachi, N., Cao, Y.Q., Contet, C., Mennicken, F., O'Donnell, D., Kieffer, B.L., Basbaum, A.I., 2009. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. *Cell* 137, 1148–1159.
- Scherrer, G., Tryoen-Toth, P., Filliol, D., Matifas, A., Laustriat, D., Cao, Y.Q., Basbaum, A.I., Dierich, A., Vonesh, J.L., Gaveriaux-Ruff, C., Kieffer, B.L., 2006. Knockin mice expressing fluorescent delta-opioid receptors uncover G protein-coupled receptor dynamics in vivo. *Proc. Natl. Acad. Sci. U. S. A.* 103, 9691–9696.
- Schnell, S.A., Staines, W.A., Wessendorf, M.W., 1999. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. *J. Histochem. Cytochem.* 47, 719–730.
- Shaner, N.C., Campbell, R.E., Steinbach, P.A., Giepmans, B.N., Palmer, A.E., Tsien, R.Y., 2004. Improved monomeric red, orange and yellow fluorescent proteins derived from *Drosophila* *Discosoma* sp. red fluorescent protein. *Nat. Biotechnol.* 22, 1567–1572.
- Shi, T.J., Hua, X.Y., Lu, X., Malkmus, S., Kinney, J., Holmberg, K., Wirz, S., Ceccatelli, S., Yaksh, T., Bartfai, T., Hokfelt, T., 2006. Sensory neuronal phenotype in galanin receptor 2 knockout mice: focus on dorsal root ganglion neurone development and pain behaviour. *Eur. J. Neurosci.* 23, 627–636.
- Shi, T.J., Xiang, Q., Zhang, M.D., Barde, S., Kai-Larsen, Y., Fried, K., Josephson, A., Gluck, L., Deyev, S.M., Zvyagin, A.V., Schulz, S., Hokfelt, T., 2014. Somatostatin and its 2A receptor in dorsal root ganglia and dorsal horn of mouse and human: expression, trafficking and possible role in pain. *Mol. Pain* 10, 12.
- Shi, T.J., Zhang, X., Berge, O.G., Erickson, J.C., Palmiter, R.D., Hokfelt, T., 1998. Effect of peripheral axotomy on dorsal root ganglion neuron phenotype and autonomy behaviour in neuropeptide Y-deficient mice. *Regul. Pept.* 75–76, 161–173.
- Spitzer, N., Sammons, G.S., Price, E.M., 2011. Autofluorescent cells in rat brain can be convincing impostors in green fluorescent reporter studies. *J. Neurosci. Methods* 197, 48–55.
- Spriggs, K.A., Bushell, M., Willis, A.E., 2010. Translational regulation of gene expression during conditions of cell stress. *Mol. Cell* 40, 228–237.
- Sten Shi, T.J., Zhang, X., Holmberg, K., Xu, Z.Q., Hokfelt, T., 1997. Expression and regulation of galanin-R2 receptors in rat primary sensory neurons: effect of axotomy and inflammation. *Neurosci. Lett.* 237, 57–60.
- Sulzer, D., Mosharov, E., Talloczy, Z., Zucca, F.A., Simon, J.D., Zecca, L., 2008. Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. *J. Neurochem.* 106, 24–36.
- Sweerts, B.W., Jarrott, B., Lawrence, A.J., 2000. [1-125]-galanin binding sites in the human nodose ganglion. *Life Sci.* 67, 2685–2690.
- Terman, A., Brunk, U.T., 2004. Aging as a catabolic malfunction. *Int. J. Biochem. Cell Biol.* 36, 1400–1404.
- Thakur, M., Crow, M., Richards, N., Davey, G.J., Levine, E., Kelleher, J.H., Agley, C.C., Denk, F., Harridge, S.D., McMahon, S.B., 2014. Defining the nociceptor transcriptome. *Front. Mol. Neurosci.* 7, 87.
- Trueta, C., De-Miguel, F.F., 2012. Extrasynaptic exocytosis and its mechanisms: a source of molecules mediating volume transmission in the nervous system. *Front. Physiol.* 3, 319.
- Usuku, T., Nishi, M., Morimoto, M., Brewer, J.A., Muglia, L.J., Sugimoto, T., Kawata, M., 2005. Visualization of glucocorticoid receptor in the brain of green fluorescent protein-glucocorticoid receptor knockin mice. *Neuroscience* 135, 1119–1128.
- Villar, M.J., Cortes, R., Theodorsson, E., Wiesenfeld, H.Z., Schalling, M., Fahrenkrug, J., Emson, P.C., Hokfelt, T., 1989. Neuropeptide expression in rat dorsal root ganglion cells and spinal cord after peripheral nerve injury with special reference to galanin. *Neuroscience* 33, 587–604.
- Voigt, A., Hubner, S., Lossow, K., Hermans-Borgmeyer, I., Boehm, U., Meyerhof, W., 2012. Genetic labeling of Tas1r1 and Tas2r131 taste receptor cells in mice. *Chem. Senses* 37, 897–911.
- Wang, H.B., Zhao, B., Zhong, Y.Q., Li, K.C., Li, Z.Y., Wang, Q., Lu, Y.J., Zhang, Z.N., He, S.Q., Zheng, H.C., Wu, S.X., Hokfelt, T.G., Bao, L., Zhang, X., 2010. Coexpression of delta- and mu-opioid receptors in nociceptive sensory neurons. *Proc. Natl. Acad. Sci. U. S. A.* 107, 13117–13122.
- Wang, S., He, C., Maguire, M.T., Clemmons, A.L., Burrier, R.E., Guzzi, M.F., Strader, C.D., Parker, E.M., Bayne, M.L., 1997. Genomic organization and functional characterization of the mouse GalR1 galanin receptor. *FEBS Lett.* 411, 225–230.
- Waters, S.M., Krause, J.E., 2000. Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. *Neuroscience* 95, 265–271.
- Webbing, K.E., Runesson, J., Bartfai, T., Langel, U., 2012. Galanin receptors and ligands. *Front. Endocrinol.* 3, 146.
- Wirz, S.A., Davis, C.N., Lu, X., Zal, T., Bartfai, T., 2005. Homodimerization and internalization of galanin type 1 receptor in living CHO cells. *Neuropeptides* 39, 535–546.
- Xia, S., Dun, X.P., Hu, P.S., Kjaer, S., Zheng, K., Qian, Y., Solen, C., Xu, T., Fredholm, B., Hokfelt, T., Xu, Z.Q., 2008. Postendocytotic traffic of the galanin R1 receptor: a lysosomal signal motif on the cytoplasmic terminus. *Proc. Natl. Acad. Sci. U. S. A.* 105, 5609–5613.
- Xia, S., Kjaer, S., Zheng, K., Hu, P.S., Bai, L., Jia, J.Y., Rigler, R., Pramanik, A., Xu, T., Hokfelt, T., Xu, Z.Q., 2004. Visualization of a functionally enhanced GFP-tagged galanin R2 receptor in PC12 cells: constitutive and ligand-induced internalization. *Proc. Natl. Acad. Sci. U. S. A.* 101, 15207–15212.
- Xu, Z.Q., Shi, T.J., Landry, M., Hokfelt, T., 1996. Evidence for galanin receptors in primary sensory neurones and effect of axotomy and inflammation. *Neuroreport* 8, 237–242.
- Yasuda, M., Tanaka, Y., Ryu, M., Tsuda, S., Nakazawa, T., 2014. RNA sequence reveals mouse retinal transcriptome changes early after axonal injury. *PLoS One* 9, e93258.
- Zeilhofer, H.U., Wildner, H., Evenes, G.E., 2012. Fast synaptic inhibition in spinal sensory processing and pain control. *Physiol. Rev.* 92, 193–235.
- Zeng, J.W., Cheng, S.Y., Liu, X.H., Zhao, Y.D., Xiao, Z., Burnstock, G., Ruan, H.Z., 2013. Expression of P2X5 receptors in the rat, cat, mouse and guinea pig dorsal root ganglion. *Histochem. Cell Biol.* 139, 549–557.
- Zeng, X., Chen, J., Sanchez, J.F., Coggiano, M., Dillon-Carter, O., Petersen, J., Freed, W.J., 2003. Stable expression of hrGFP by mouse embryonic stem cells: promoter activity in the undifferentiated state and during dopaminergic neural differentiation. *Stem Cells* 21, 647–653.
- Zhang, J.P., Xu, Q., Yuan, X.S., Cherasse, Y., Schiffmann, S.N., de Kerchove d'Exaerde, A., Qu, W.M., Urade, Y., Lazarus, M., Huang, Z.L., Li, R.X., 2013. Projections of nucleus accumbens adenosine A2A receptor neurons in the mouse brain and their implications in mediating sleep-wake regulation. *Front. Neuroanat.* 7, 43.
- Zhang, X., Aman, K., Hokfelt, T., 1995a. Secretory pathways of neuropeptides in rat lumbar dorsal root ganglion neurons and effects of peripheral axotomy. *J. Comp. Neurol.* 352, 481–500.
- Zhang, X., Bao, L., Xu, Z.Q., Kopp, J., Arvidsson, U., Elde, R., Hokfelt, T., 1994. Localization of neuropeptide Y Y1 receptors in the rat nervous system with special reference to somatic receptors on small dorsal root ganglion neurons. *Proc. Natl. Acad. Sci. U. S. A.* 91, 11738–11742.
- Zhang, X., Ji, R.R., Nilsson, S., Villar, M., Ubink, R., Ju, G., Wiesenfeld, H.Z., Hokfelt, T., 1995b. Neuropeptide Y and galanin binding sites in rat and monkey lumbar dorsal root ganglia and spinal cord and effect of peripheral axotomy. *Eur. J. Neurosci.* 7, 367–380.
- Zhao, X., Seese, R.R., Yun, K., Peng, T., Wang, Z., 2013. The role of galanin system in modulating depression, anxiety, and addiction-like behaviors after chronic restraint stress. *Neuroscience* 246, 82–93.